GYRE Dividend: Gyre Therapeutics Inc Yield Insights

Income

Balance sheet

Cash flow

Annual

Quarterly

GYRE Income

Financials in millions USD. Fiscal year is February - January.

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Revenue	107	105	113	0	7	20
Revenue Growth (YoY)	-44%	-7%	--	-100%	-65%	--
Cost of Revenue	4	3	4	0	7	9
Gross Profit	102	101	108	0	0	11
Selling, General & Admin	77	73	75	16	18	16
Research & Development	12	12	13	12	68	52
Operating Expenses	90	85	89	29	87	68
Other Non Operating Income (Expenses)	2	5	-10	0	0	0
Pretax Income	15	23	-76	-7	-87	-56
Income Tax Expense	3	5	8	0	--	--
Net Income	6	12	-92	-8	-87	-56
Net Income Growth	-108%	-112.99%	1,050%	-91%	55%	2%
Shares Outstanding (Diluted)	103.97	102.29	65.83	2.1	2.04	1.28
Shares Change (YoY)	1%	55%	3,035%	3%	59%	60%
EPS (Diluted)	0.06	0.11	-1.41	-3.92	-43.1	-43.93
EPS Growth	-109%	-108%	-64%	-91%	-2%	-36%
Free Cash Flow	1	-6	17	-33	-84	-55
Free Cash Flow Per Share	0	-0.05	0.25	-15.71	-41.17	-42.96
Gross Margin	95.32%	96.19%	95.57%	0%	0%	55%
Operating Margin	10.28%	15.23%	16.81%	0%	-1,242.85%	-280%
Profit Margin	5.6%	11.42%	-81.41%	0%	-1,242.85%	-280%
Free Cash Flow Margin	0.93%	-5.71%	15.04%	0%	-1,200%	-275%
EBITDA	13	17	20	-29	-87	-56
EBITDA Margin	12.14%	16.19%	17.69%	0%	-1,242.85%	-280%
D&A For EBITDA	2	1	1	0	0	0
EBIT	11	16	19	-29	-87	-56
EBIT Margin	10.28%	15.23%	16.81%	0%	-1,242.85%	-280%
Effective Tax Rate	20%	21.73%	-10.52%	0%	--	--